AVAILABLE MEDICINE FOR Dabigatran Etexilate
There are no products to list.
Introduction to Dabigatran Etexilate
Dabigatran Etexilate is an anticoagulant that belongs to the class of direct thrombin inhibitors. It is sold under the brand name Pradaxa and is used to reduce the risk of stroke and systemic embolism in patients with non-valvular atrial fibrillation (NVAF).
How it Works:
Dabigatran Etexilate works by directly inhibiting thrombin, an enzyme essential for blood clot formation. By blocking thrombin, it prevents the development of harmful blood clots.
Uses of Dabigatran Etexilate
- Prevention of stroke and embolism in patients with NVAF.
- Treatment and prevention of deep vein thrombosis (DVT) and pulmonary embolism (PE).
- Prevention of clotting after hip replacement surgery.
Side Effects of Dabigatran Etexilate
- Bleeding (e.g., bruising, nosebleeds).
- Gastrointestinal discomfort (nausea, indigestion).
- In rare cases, serious bleeding or allergic reactions may occur.
FDA Approval:
Dabigatran was approved by the FDA in October 2010 for preventing stroke and systemic embolism in patients with NVAF.
